New drug combo tested for Tough-to-Treat breast cancer
NCT ID NCT07498478
Summary
This study is testing whether combining two drugs, tinengotinib and fulvestrant, can help control advanced breast cancer that has stopped responding to standard hormone therapies. It will involve about 94 people with HR-positive, HER2-negative or low-expressing breast cancer that has returned or spread. The research aims to find the best dose and see if the combination works better than tinengotinib alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
NOT_YET_RECRUITINGBeijing, China
Contact
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100021, China
Contact
-
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITINGShanghai, China
Contact
-
Guangdong Provincial People's Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
Contact
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, China
Contact
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, China
Contact
-
Linyi Cancer Hospital
RECRUITINGLinyi, Shandong, China
Contact
-
Shandong Cancer Hospital
NOT_YET_RECRUITINGJinan, Shandong, China
Contact
-
Southwest Hospital
NOT_YET_RECRUITINGChongqing, China
Contact
-
The First Medical Center, Chinese PLA General Hospital
NOT_YET_RECRUITINGBeijing, China
Contact
-
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITINGTianjin, China
Contact
-
Zhejiang Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
Contact
-
Zhongnan Hospital of Wuhan University
NOT_YET_RECRUITINGWuhan, Hubei, China
Contact
Conditions
Explore the condition pages connected to this study.